COVID-19: Vaccines and Therapeutics
New data from Pfizer Inc. indicates that its COVID-19 vaccine is more stable than previously believed when stored -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators.
President Biden told a group of G-7 leaders that the U.S. will support the COVAX alliance tasked with distributing COVID-19 vaccines to 92 low- and middle-income countries.
The AHA recently launched a new webpage dedicated to disseminating accessible information focused on addressing the equity issues in COVID-19 testing, treatment and vaccine administration efforts.
Safety monitoring during the first month of the COVID-19 national vaccination program shows “reassuring safety profiles” for the Pfizer and Moderna COVID-19 vaccines, the Centers for Disease Control and Prevention reported.
Advancing health equity within communities of color disproportionately impacted by COVID-19 — and getting the facts straight about reasons for hesitancy over receiving vaccines — are priority issues for government policy influencers and health care organization leaders.
With our nation’s COVID-19 vaccine administration rollout underway, policy influencers and advocacy groups are focusing on communities of color that have been disproportionately impacted by the fluctuating pandemic.
The people working in hospitals and health systems are trusted sources of information. Answering questions, sharing personal reasons for getting vaccinated, and respecting concerns of those not yet ready to get their vaccine are all powerful ways the health care field can help their communities…
The federal government will increase its weekly shipments of COVID-19 vaccines to states, the White House announced.
The Centers for Disease Control and Prevention released guidance on COVID-19 vaccination planning, training and administration for health care providers who vaccinate homebound persons.
The departments of Health and Human Services and Defense ordered 200 million more doses of COVID-19 vaccines authorized for emergency use, half from Pfizer for $2 billion and the rest from Moderna for about $1.7 billion.